Second-line rescue treatment of Helicobacter pylori infection: Where are we now?

doi:10.3748/wjg.v24.i40.4548

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 24, Issue 40

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (12151)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

1000

WORD

289

HTML

7367

Figures (1-1)

515

Tables (1-1)

508

Sum=9679

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

837

Download

1635

Sum=2472

Oct 28, 2018 (publication date) through Oct 31, 2025

Times Cited of This Article

Times Cited (34)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Minireviews

World J Gastroenterol. Oct 28, 2018; 24(40): 4548-4553
Published online Oct 28, 2018. doi: 10.3748/wjg.v24.i40.4548

Table 1 Regimens for second-line anti-Helicobacter pylori therapy

Regimen	Drug						Duration of therapy
Regimen	PPI	Bismuth	Levo	Amox	Tetra	Metro	Duration of therapy
Bismuth-containing quadruple therapy	SD, b.i.d.	120 mg, q.i.d.			500 mg, q.i.d.	500 mg, t.i.d.	10-14 d
Levofloxacin-containing triple therapy	SD, b.i.d.		500 mg, q.d.	1 g, b.i.d.			10-14 d
Levofloxacin-amoxicillin quadruple therapy	SD, b.i.d.	120 mg, q.i.d.	500 mg, q.d.	1 g, b.i.d.			10-14 d
Tetracycline-levofloxacin quadruple therapy	SD, b.i.d.	120 mg, q.i.d.	500 mg, q.d.		500 mg, q.i.d.		10 d
High-dose dual therapy	SD, q.i.d.			750 mg, b.i.d.			14 d

PPI: Proton pump inhibitor; Levo: Levofloxacin; Amox: Amoxicillin; Tetra: Tetracycline; Metro: Metronidazole.

Full Size Table

Citation: Lin TF, Hsu PI. Second-line rescue treatment of Helicobacter pylori infection: Where are we now? World J Gastroenterol 2018; 24(40): 4548-4553
URL: https://www.wjgnet.com/1007-9327/full/v24/i40/4548.htm
DOI: https://dx.doi.org/10.3748/wjg.v24.i40.4548